Pharmaceuticals, Biotechnology and Healthcare
We provide an extensive range of legal advice to companies and have an unparalleled perspective of the sector. Our clients range from investors, start-up companies and large and medium-sized organisations, to universities and research institutions and emerging biotechnology ventures.
Our team includes corporate, competition and regulatory, dispute resolution, environmental and intellectual property lawyers and lawyers with medical or scientific backgrounds.
We advise on:
- commercial agreements including licensing, collaboration and research and development
- strategies for managing and commercialising patent and trade mark portfolios
- disputes in the High Court, Court of Appeal, European Patent Office and other registries
- cross-border litigation and international strategies
- mergers and acquisitions, joint ventures and flotations
- specialist areas such as tax and environment and have experience in dealing with competition issues arising out of transactions from licences to mergers
We are actively involved in legal issues. Members of our team sit on the Intellectual Property Advisory Committee of the BioIndustry Association (BIA), the industry association for biotechnology companies and the editorial board of the Bio-Science Law Review.
Slaughter and May has 'an ability not just to identify potential issues, but also to propose creative solutions to them' The Legal 500, 2013View all Pharmaceuticals, Biotechnology and Healthcare media comments
Our key experience includes advising:
GlaxoSmithKline in relation to the pharmaceutical sector inquiry conducted by the European Commission.
GlaxoSmithKline on its agreement with Pfizer to create a new world-leading HIV company with a broad product portfolio of 11 marketed products and an industry-leading pipeline of 6 innovative and targeted medicines.
GE Healthcare Life Sciences Limited, a wholly owned subsidiary of General Electric Company, on the acquisition of Whatman plc, a global supplier of filtration technology and separation products, for approximately £363 million.
Alliance Boots in relation to its recommended acquisition by AB Acquisitions Limited. We further advised in relation to the ECMR and other filing requirements arising from the acquisition, which was cleared by the European Commission in June 2007.
GlaxoSmithKline on a variety of global supply and development agreements for pharmaceutical and consumer healthcare products. Also advising on product licence agreements, patent and know-how licences.
Bayer, one of the world’s leading innovative companies in the healthcare and medicinal products industry, on the disposal of its diagnostics business to Siemens AG, Munich for EUR 4.2 billion.
Cephalon Inc., a NASDAQ listed international biopharmaceutical company, on the acquisition of Zeneus Holdings Ltd for approximately US$360 million in cash.
Stem Cells Inc in relation to a stem cell cross-licence between Stem Cells Inc and ReNeuron Limited and the acquisition by Stem Cells Inc of an equity interest in ReNeuron Group plc.
Shire on its acquisition of Transkaryoptic Therapies, a US-based biopharmaceutical company researching, developing and commercialising therapeutics primarily for the treatment of rare genetic diseases caused by protein deficiencies.
Thermo Fisher Scientific, a US manufacturer and supplier of scientific and analytical instruments and laboratory equipment, on the UK competition law aspects of its acquisition of Werner Reifferscheidt.